Premium
Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC)
Author(s) -
Meng En,
Hsu YuChao,
Chuang YaoChi
Publication year - 2018
Publication title -
luts: lower urinary tract symptoms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.451
H-Index - 15
eISSN - 1757-5672
pISSN - 1757-5664
DOI - 10.1111/luts.12214
Subject(s) - interstitial cystitis , medicine , bladder pain syndrome , hyaluronic acid , urology , chondroitin sulfate , urinary system , anatomy , glycosaminoglycan
Bladder pain syndrome (BPS)/interstitial cystitis (IC) is a chronic symptom complex that may cause bothersome storage symptoms and pain or discomfort of the bladder, adversely affecting a patient's quality of life. The etiology of IC/BPS remains unclear, and its cause may be multifactorial. Diagnosis of IC/BPS is based on clinical features, and the possibility of other conditions must be ruled out first. Although no definitive treatment is currently available for IC/BPS, various intravesical therapies are used for IC/BPS, including heparin, hyaluronic acid, chondroitin sulfate, pentosan polysulfate, dimethylsulfoxide, liposomes, and botulinum onabotulinumtoxinA (BoNT‐A). This review summarizes the intravesical therapy for IC/BPS and discusses recent advances in the instillation of liposomal‐mediated BoNT‐A and other newly developed intravesical therapies.